Ling-Jun Feng1, Hong-Ling Liu2, Qiang Tan3, Peng Jin4. 1. Department of Thyroid & Breast Surgery, Affiliated Hospital of Weifang Medical University Weifang 261031, Shandong Province, China. 2. Department of Health Examination, Affiliated Hospital of Weifang Medical University Weifang 261031, Shandong Province, China. 3. Department of Respiratory Medicine, Weifang People's Hospital Weifang 261041, Shandong Province, China. 4. Department of Anus & Intestine Surgery, Affiliated Hospital of Weifang Medical University Weifang 261031, Shandong Province, China.
Abstract
PURPOSE: we aimed to investigate the receptor for advanced glycation end products (RAGE) -374T/A polymorphism and breast cancer risk in a Chinese population. METHODS: The study subjects included 188 women with histologically confirmed breast cancer and 210 controls. The RAGE genotypes were determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) assay. Pearson's χ(2) test was used to test the association between cases and controls and genotype frequencies. The association between the polymorphism and risk of breast cancer was estimated by odds ratio (OR) and 95% confidence interval (95% CI). RESULTS: The AA genotype was significantly higher in breast cancer patients than in controls (37.77% vs. 28.10%, P = 0.002). Furthermore, the A allele frequency was significantly higher in the case group than in the control group (55.32% vs. 42.14%, P < 0.001). With the TT genotype as reference, the adjusted OR for AA homozygous carriers reached to 0.36 (95% CI: 0.17-0.88; P = 0.03). Under the dominant model of inheritance, the TA+AA genotype was associated with significantly decreased risk for breast cancer (adjusted OR = 0.38, 95% CI = 0.27-0.87; P = 0.02). The A allele carriage also presented a lower risk for breast cancer (adjusted OR = 0.42; 95% CI, 0.33-0.91; P = 0.04). CONCLUSION: Our findings suggest that the polymorphic variants of RAGE-374T/A may have an influence on breast cancer risk among Chinese women.
PURPOSE: we aimed to investigate the receptor for advanced glycation end products (RAGE) -374T/A polymorphism and breast cancer risk in a Chinese population. METHODS: The study subjects included 188 women with histologically confirmed breast cancer and 210 controls. The RAGE genotypes were determined using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) assay. Pearson's χ(2) test was used to test the association between cases and controls and genotype frequencies. The association between the polymorphism and risk of breast cancer was estimated by odds ratio (OR) and 95% confidence interval (95% CI). RESULTS: The AA genotype was significantly higher in breast cancerpatients than in controls (37.77% vs. 28.10%, P = 0.002). Furthermore, the A allele frequency was significantly higher in the case group than in the control group (55.32% vs. 42.14%, P < 0.001). With the TT genotype as reference, the adjusted OR for AA homozygous carriers reached to 0.36 (95% CI: 0.17-0.88; P = 0.03). Under the dominant model of inheritance, the TA+AA genotype was associated with significantly decreased risk for breast cancer (adjusted OR = 0.38, 95% CI = 0.27-0.87; P = 0.02). The A allele carriage also presented a lower risk for breast cancer (adjusted OR = 0.42; 95% CI, 0.33-0.91; P = 0.04). CONCLUSION: Our findings suggest that the polymorphic variants of RAGE-374T/A may have an influence on breast cancer risk among Chinese women.
Entities:
Keywords:
Receptor for advanced glycation end products; breast cancer; polymorphisms; risk
Authors: M A Hofmann; S Drury; C Fu; W Qu; A Taguchi; Y Lu; C Avila; N Kambham; A Bierhaus; P Nawroth; M F Neurath; T Slattery; D Beach; J McClary; M Nagashima; J Morser; D Stern; A M Schmidt Journal: Cell Date: 1999-06-25 Impact factor: 41.582
Authors: A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt Journal: Nature Date: 2000-05-18 Impact factor: 49.962
Authors: Barry I Hudson; Anastasia Z Kalea; Maria Del Mar Arriero; Evis Harja; Eric Boulanger; Vivette D'Agati; Ann Marie Schmidt Journal: J Biol Chem Date: 2008-10-15 Impact factor: 5.157
Authors: M A Hofmann; S Drury; B I Hudson; M R Gleason; W Qu; Y Lu; E Lalla; S Chitnis; J Monteiro; M H Stickland; L G Bucciarelli; B Moser; G Moxley; S Itescu; P J Grant; P K Gregersen; D M Stern; A M Schmidt Journal: Genes Immun Date: 2002-05 Impact factor: 2.676
Authors: Saeid Ghavami; Iran Rashedi; Brian M Dattilo; Mehdi Eshraghi; Walter J Chazin; Mohammad Hashemi; Sebastian Wesselborg; Claus Kerkhoff; Marek Los Journal: J Leukoc Biol Date: 2008-03-13 Impact factor: 4.962
Authors: Petra Tesarová; Marta Kalousová; Marie Jáchymová; Oto Mestek; Lubos Petruzelka; Tomás Zima Journal: Cancer Invest Date: 2007-12 Impact factor: 2.176